Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis
Metrics: PDF 722 views | HTML 1159 views | ?
Kai Wang1,*, Chenan Guan3,*, Junhui Yu1,*, Xiaoxiao Jin1, Ling Sun1, Lingzhi Zheng1, Liang Xia2 and Yuquan Zhang4
1Department of Obstetrics and Gynecology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang Province 317000, China
2Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province 310022, China
3Department of Kidney Internal Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang Province 317000, China
4Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province 226001, China
*These authors have contributed equally to this work
Lingzhi Zheng, email: email@example.com
Liang Xia, email: firstname.lastname@example.org
Yuquan Zhang, email: email@example.com
Keywords: epithelial ovarian cancer, HER-2/neu, prognosis, meta-analysis
Received: December 02, 2016 Accepted: July 26, 2017 Published: September 06, 2017
This study aimed to conduct a meta-analysis to investigate the association between human epidermal growth factor receptor 2 (HER-2/neu) expression and survival in patients with epithelial ovarian cancer (EOC). HER-2/neu is one of the most frequently studied molecular biological parameters in EOC, but its prognostic impact has not been fully assessed. PubMed and Embase were searched for studies that reported HER-2/neu expression and survival in patients with EOC. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). Hazard ratios (HRs) with 95% confidence interval (CI) were determined using Mantel–Haenszel random-effects model. Publication bias was investigated using funnel plots and Egger’s test. A total of 56 studies (N=7212) were included in the analysis. The results showed that patients possessing HER-2/neu expression had significant disadvantages in OS (HR = 1.41; 95%CI, 1.31 to 1.51; P < 0.001) and PFS (HR = 1.38; 95% CI, 1.23–1.56; P < 0.001). The trim-and-fill method, Copas model, and subgroup analyses stratified by the study characteristics confirmed the robustness of the results. The present study findings provided further indication that HER-2/neu expression in patients with EOC has an adverse impact on OS and PFS.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.